US 12,453,770 B2
CLEC9A binding agents
Jan Tavernier, Balegem (BE); Nikolai Kley, Newton, MA (US); Anje Cauwels, Merelbeke (BE); and Sarah Gerlo, Ghent (BE)
Assigned to Orionis Biosciences BV, Ghent (BE); VIB VZW, Ghent (BE); and Universiteit Gent, Ghent (BE)
Filed by Orionis Biosciences BV, Ghent (BE); VIB VZW, Ghent (BE); and Universiteit Gent, Ghent (BE)
Filed on Apr. 5, 2021, as Appl. No. 17/222,043.
Application 17/222,043 is a continuation of application No. 16/075,318, granted, now 11,001,631, previously published as PCT/EP2017/052544, filed on Feb. 6, 2017.
Claims priority of provisional application 62/411,805, filed on Oct. 24, 2016.
Claims priority of provisional application 62/353,607, filed on Jun. 23, 2016.
Claims priority of provisional application 62/335,965, filed on May 13, 2016.
Claims priority of provisional application 62/335,979, filed on May 13, 2016.
Claims priority of provisional application 62/335,968, filed on May 13, 2016.
Claims priority of provisional application 62/335,880, filed on May 13, 2016.
Claims priority of provisional application 62/336,030, filed on May 13, 2016.
Claims priority of provisional application 62/291,769, filed on Feb. 5, 2016.
Claims priority of provisional application 62/291,772, filed on Feb. 5, 2016.
Claims priority of provisional application 62/291,779, filed on Feb. 5, 2016.
Claims priority of provisional application 62/291,776, filed on Feb. 5, 2016.
Claims priority of provisional application 62/291,774, filed on Feb. 5, 2016.
Prior Publication US 2022/0356253 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 14/56 (2006.01); C07K 14/715 (2006.01); C07K 16/24 (2006.01)
CPC A61K 39/395 (2013.01) [A61K 38/00 (2013.01); A61P 35/00 (2018.01); C07K 16/00 (2013.01); C07K 16/2851 (2013.01); A61K 2039/505 (2013.01); A61K 2039/57 (2013.01); C07K 14/56 (2013.01); C07K 14/7156 (2013.01); C07K 16/249 (2013.01); C07K 16/2815 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2887 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/66 (2013.01); C07K 2317/74 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/33 (2013.01); C07K 2319/735 (2013.01); C07K 2319/74 (2013.01); Y02A 50/30 (2018.01)] 11 Claims
 
1. A composition comprising a targeting moiety that comprises a recognition domain that recognizes and binds to C-type lectin domain family 9 member A (Clec9A), wherein the targeting moiety comprises three complementarity determining regions (CDR1, CDR2, and CDR3) wherein:
(a) CDR1 comprises an amino acid sequence selected from any one of SEQ ID NOs: 2-21, and GSSDSINAMG (SEQ ID NO: 324);
(b) CDR2 comprises an amino acid sequence selected from any one of SEQ ID NOs: 22-43; and
(c) CDR3 comprises an amino acid sequence selected from any one of SEQ ID NOs: 44-58, LGR, and VIK.